Global Pharma CEOs See Compensation Shifts Amid Strong Drug Demand and Regulatory Changes

Global major pharmaceutical companies have finalized their annual performance results, prompting a new ranking of chief executive officer (CEO) compensation. Executives whose firms benefited from strong demand for medicines reported significant pay rises. Conversely, CEOs whose one‑time stock awards decreased or who faced changing market conditions saw their compensation rankings drop. The compensation picture is drawing attention because it occurs alongside regulatory shifts following the start of the second Trump administration. Last year, U.S. health authorities pursued large cuts to research and development (R&D) budgets and the Food and Drug Administration (FDA) altered its policy direction, influencing the pharmaceutical sector.